Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab tirumotecan in EGFR uncommon mutation NSCLC (phase II, single-arm)
ChiCTR2500114453Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500114453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114453.